SWX:IDIABiotechs
A Look At Idorsia’s (SWX:IDIA) Valuation After Its Lucerastat Phase 3 Program Agreement With The FDA
Why lucerastat’s new Phase 3 plan matters for Idorsia shareholders
Idorsia (SWX:IDIA) has agreed with the US FDA on a Phase 3 registration program for lucerastat in Fabry disease, centered on kidney outcomes and backed by recently published MODIFY trial data.
For you as an investor, this means lucerastat is moving from exploratory late stage data into a clearly defined path that is intended to support a potential marketing application, with health authority alignment already in place.
See our...